[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100482178":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":29,"responsibleParty":69,"collaborators":18,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":18,"enrollmentInfo":81,"targetDuration":18,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":31,"whyStopped":18,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Institut Curie","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"single arm for all patients","EXPERIMENTAL","single arm for all patients tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.\n\nblood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery.",[13],"Other: single arm for all patients",[15],{"type":6,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"* tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.\n* blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery.",[9],null,[20],{"name":21,"affiliation":22,"role":23},"Clémence BASSE, MD","Institut Curie Paris","STUDY_DIRECTOR",[25],{"name":21,"role":26,"phone":27,"phoneExt":18,"email":28},"CONTACT","01 56 24 55 39","clemence.basse@curie.fr",[30,47,56],{"facility":22,"status":31,"city":32,"state":18,"zip":18,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Paris","France","FR",{"type":36,"coordinates":37},"Point",[38,39],2.3488,48.85341,{"lat":39,"lon":38},[42,45],{"name":43,"role":26,"phone":18,"phoneExt":18,"email":44},"Nicolas Girard, MD","nicolas.girard2@curie.fr",{"name":43,"role":46,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"facility":48,"status":31,"city":32,"state":18,"zip":18,"country":33,"countryCode":34,"cosmosGeoPoint":49,"geoPoint":51,"contacts":52},"Institut Mutualiste Montsouris",{"type":36,"coordinates":50},[38,39],{"lat":39,"lon":38},[53,55],{"name":54,"role":26,"phone":18,"phoneExt":18,"email":18},"Alessio MARIOLO, MD",{"name":54,"role":46,"phone":18,"phoneExt":18,"email":18},{"facility":57,"status":31,"city":58,"state":18,"zip":18,"country":33,"countryCode":34,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Hôpital FOCH","Suresnes",{"type":36,"coordinates":60},[61,62],2.22929,48.87143,{"lat":62,"lon":61},[65,68],{"name":66,"role":26,"phone":18,"phoneExt":18,"email":67},"Edouard SAGE, MD","e.sage@hopital-foch.com",{"name":66,"role":46,"phone":18,"phoneExt":18,"email":18},{"type":70,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100482178","characterisation-of-the-immune-infiltrate-and-molecular-features-of-thymic-epithelial-tumors-tumors-tets-immuno-tet-100482178",false,"NCT05558644","Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs) (IMMUNO-TET)","Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)","IMMUNO-TET","Inclusion Criteria:\n\n1. Patient with suspicion of localised thymic epithelial tumour.\n2. Age ≥ 18 years.\n3. Treatment-naïve patient for this disease.\n4. Patient with an indication for thymectomy and thymomectomy in one of the partner centers.\n5. Signed informed consent form of the patient.\n\nExclusion Criteria:\n\n1. Neoadjuvant chemotherapy.\n2. No social security affiliation.\n3. Person under legal protection.\n4. Other neoplasia in progress or cured within the last 3 years (except for operated carcinoma in situ).","ALL","18 Years",{"count":82,"type":83},50,"ESTIMATED","INTERVENTIONAL",[86],"NA","The IMMUNO-TET trial aims to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with localised thymic epithelial tumour (TET).",[89],"Cancer",[91],"thymic epithelial tumors","2025-09-02",{"date":94,"type":95},"2025-09-08","ACTUAL",{"date":97,"type":95},"2023-08-03",{"date":99,"type":83},"2026-10-05",{"name":5,"class":6},3]